Online citations, reference lists, and bibliographies.
← Back to Search

The Studies Of PLGA Nanoparticles Loading Atorvastatin Calcium For Oral Administration In Vitro And In Vivo

Zhenbao Li, W. Tao, D. Zhang, Chunnuan Wu, Binbin Song, S. Wang, Tianyang Wang, Mingming Hu, Xiaohong Liu, Y. Wang, Y. Sun, J. Sun
Published 2017 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Graphical Abstract Unlabelled image
This paper references
10.1161/01.ATV.15.5.678
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
J. W. Nawrocki (1995)
10.2147/DDDT.S90016
Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers
J. Zhou (2015)
10.2165/00003088-200342130-00005
Clinical Pharmacokinetics of Atorvastatin
H. Lennernäs (2003)
10.1002/bmc.3474
A rapid and sensitive LC-MS/MS method for evaluation of the absolute oral bioavailability of a novel c-Met tyrosine kinase inhibitor QBH-196 in rats.
Q. Zhang (2015)
10.1016/j.xphs.2015.11.019
Intra-articular Administration of Chitosan Thermosensitive In Situ Hydrogels Combined With Diclofenac Sodium-Loaded Alginate Microspheres.
X. Qi (2016)
10.1016/j.ijpharm.2009.02.015
Micronization of atorvastatin calcium by antisolvent precipitation process.
H. Zhang (2009)
10.2147/IJN.S83520
Development and optimization of a self-microemulsifying drug delivery system for ator vastatin calcium by using d-optimal mixture design
D. W. Yeom (2015)
10.1002/jssc.201500954
Detection of related substances in polyene phosphatidyl choline extracted from soybean and in its commercial capsule by comprehensive supercritical fluid chromatography with mass spectrometry compared with HPLC with evaporative light scattering detection.
Qikun Jiang (2016)
10.2165/00003495-199753050-00011
Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
A. Lea (1997)
10.1016/S0169-409X(97)00048-3
Biodegradation and biocompatibility of PLA and PLGA microspheres
J. Anderson (1997)
10.1016/J.JCIS.2006.07.031
Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms.
M. J. Santander-Ortega (2006)
10.1016/j.nano.2010.02.002
In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems.
B. Semete (2010)
10.3390/molecules19010342
Development of a Supercritical Fluid Chromatography-Tandem Mass Spectrometry Method for the Determination of Azacitidine in Rat Plasma and Its Application to a Bioavailability Study
D. Li (2013)
10.1208/s12249-011-9673-3
Enhanced Bioavailability of Atorvastatin Calcium from Stabilized Gastric Resident Formulation
F. N. Khan (2011)
10.1016/j.ejpb.2008.01.007
Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
M. Kim (2008)
10.1016/j.jchromb.2013.11.029
Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of lacidipine in beagle dog plasma and its application to a bioavailability study.
Yajie Geng (2014)
10.3797/scipharm.1201-06
Systematic Development of Self-Emulsifying Drug Delivery Systems of Atorvastatin with Improved Bioavailability Potential
F. Khan (2012)
10.1016/j.lfs.2015.05.026
Effects of carbohydrate polymers in self-microemulsified tablets on the bioavailability of atorvastatin: In vitro-in vivo study.
P. K. Biswal (2015)
Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex.
H. Lv (2012)
10.3109/10837450.2015.1108983
Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile
N. Kumar (2017)
10.1016/j.jconrel.2014.10.024
Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Xiaopeng Han (2015)
10.1001/JAMA.1996.03530260042029
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
R. Bakker-Arkema (1996)
10.1111/j.2042-7158.1997.tb06084.x
Human Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models
H. Lennernäs (1997)
10.1016/j.colsurfb.2015.03.036
Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona.
Zhenbao Li (2015)
10.1016/j.jconrel.2013.12.030
Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy.
C. Luo (2014)
10.1016/j.ijpharm.2011.05.049
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review.
S. Fredenberg (2011)
10.1161/01.CIR.79.1.8
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
D. Gordon (1989)
10.3109/21691401.2015.1041637
Development and characterization of floating spheroids of atorvastatin calcium loaded NLC for enhancement of oral bioavailability
Kritika Sharma (2016)
10.1016/j.ijpharm.2008.04.006
Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.
J. Kim (2008)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1016/j.addr.2012.09.004
Biodegradation and biocompatibility of PLA and PLGA microspheres.
Shive (1997)
10.1016/j.ejps.2011.08.001
Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats.
M. Anwar (2011)
10.1016/j.biomaterials.2012.06.019
Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
J. Wang (2012)
High-Density Lipoprotein Cholesterol and Cardiovascular Disease
D. Gordon (2005)



This paper is referenced by
10.1016/j.ajps.2018.08.010
Preparation, characterization, and in vitro/vivo evaluation of polymer-assisting formulation of atorvastatin calcium based on solid dispersion technique
W. Dong (2018)
Draft Nano-drug delivery platform for glucocorticoid use in skeletal muscle injury
Vijaykumar (2018)
10.1016/j.ejps.2020.105334
Does the trihydrate of atorvastatin calcium possess a melting point?
Chaima Tizaoui (2020)
10.1016/j.biopha.2017.07.110
Poly (d, l-lactide-co-glycolide) nanoparticles for sustained release of tacrolimus in rabbit eyes.
M. A. Kalam (2017)
10.1139/cjpp-2017-0795
Nanodrug delivery platform for glucocorticoid use in skeletal muscle injury.
V. Sutariya (2018)
10.1016/J.JDDST.2018.05.018
Physicochemical characteristics of the complexes of simvastatin and atorvastatin calcium with hydroxypropyl-β-cyclodextrin produced by mechanochemical activation
Ruiping Kong (2018)
10.1016/j.xphs.2015.11.019
Intra-articular Administration of Chitosan Thermosensitive In Situ Hydrogels Combined With Diclofenac Sodium-Loaded Alginate Microspheres.
X. Qi (2016)
10.1007/s13346-018-0565-x
Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability
Ruiping Kong (2018)
10.1080/03639045.2018.1459676
Ramizol® encapsulation into extended release PLGA micro- and nanoparticle systems for subcutaneous and intramuscular administration: in vitro and in vivo evaluation
L. Wright (2018)
10.2147/IJN.S237314
Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium
Mona G. Arafa (2020)
10.1039/d0nr01352h
Multiple targeting strategies achieve novel protein drug delivery into proapoptosis lung cancer cells by precisely inhibiting survivin.
Fabiao Hu (2020)
10.1016/j.ajps.2018.10.003
Integration of phospholipid-drug complex into self-nanoemulsifying drug delivery system to facilitate oral delivery of paclitaxel
Dawei Ding (2019)
10.1016/J.JDDST.2017.10.003
Dissolution and bioavailability enhancement of Atorvastatin: Gelucire semi-solid binary system
M. A. Shaker (2018)
10.1080/10717544.2017.1377316
Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB0,+ to deliver chemotherapeutic agents for colon cancer therapy
L. Kou (2017)
10.1016/j.ajps.2018.11.005
Redox-responsive biocompatible nanocarriers based on novel heparosan polysaccharides for intracellular anticancer drug delivery
L. Qiu (2020)
10.1016/j.mimet.2019.01.020
Antifungal efficacy of Itraconazole loaded PLGA-nanoparticles stabilized by vitamin-E TPGS: In vitro and ex vivo studies.
Adel Alhowyan (2019)
10.1016/j.colsurfb.2018.04.020
Characterization of hybrid microparticles/Montmorillonite composite with raspberry-like morphology for Atorvastatin controlled release.
P. García-Guzmán (2018)
Semantic Scholar Logo Some data provided by SemanticScholar